Sage Journals: Discover world-class research

Abstract

Objective:

Haematuria may be transient for a number of benign conditions, particularly a urinary-tract infection (UTI). We set out to determine if a negative repeat urinalysis at the time of urological assessment for patients with haematuria could predict negative investigations and whether investigations could be tailored by this test.

Methods:

This was a retrospective analysis of records for all patients attending a haematuria clinic between 16 September 2013 and 12 September 2014. This included patients with visible and non-visible (microscopic) haematuria.

Results:

There were 1138 patients, 599 with visible haematuria (VH) and 460 with non-visible haematuria (NVH). Seventy-two patients were excluded. A total of 546 patients had a positive repeat urinalysis for blood; 438 patients had a negative repeat urinalysis when tested at the haematuria clinic, 298/599 for VH and 140/460 NVH. For those who had negative repeat urinalysis, urothelial cancer was found in 15/298 VH and 1/140 NVH. The one patient with negative repeat urinalysis and NVH was found to have a grade 2 (high grade) bladder tumour. The negative predictive value for a negative repeat urinalysis in transient haematuria was 0.95 for VH and 0.99 for NVH. Twenty-nine patients with VH and repeat negative urinalysis on assessment had a positive urine culture suggesting a UTI as a cause. None of these patients was found to have urothelial cancer (p = 0.0413).

Conclusion:

Patients who experience transient VH and subsequent repeat negative urinalysis in the absence of infection have a 5% chance of urothelial cancer and should still be investigated. For those with transient NVH, the probability of finding a urothelial cancer is <1%, although we did find a high-grade bladder tumour in this group. If patients have a positive urine culture and a negative repeat urinalysis following treatment, they could be spared haematuria investigations.

Keywords

Bladder cancer haematuria negative predictive value non-visible haematuria urinalysis urothelial carcinoma visible haematuria

Get full access to this article

View all access options for this article.

References

Khadra

Pickard

Charlton

. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000; 163: 524–527.

Edwards

Dickinson

Natale

. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Intl 2006; 97: 301–305.

Sultana

Goodman

Byrne

. Microscopic haematuria: urological investigation using a standard protocol. Br J Urol 1996; 78: 691.

Jhamb

Lin

Ballow

. Urinary tract diseases and bladder cancer risk: a case-control study. Cancer Causes Control 2007; 18: 839–845.

Rodgers

Nixon

Hempel

. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess 2006; 10: iii–iv, xi–259.

Parekattil

Fisher

Kogan

. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer. J Urol 2003; 169: 917–920.

Bromage

Liew

Moore

. The economic implications of unsuspected findings from CT urography performed for haematuria. Br J Radiol 2012; 85: 1303–1306.

Davis

Jones

Barocas

. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol 2012; 188: 2473–2481.

Lynch

Waymont

Dunn

. Repeat testing for haematuria and underlying urological pathology. Br J Urol 1994; 74: 730–732.

10.

National Collaborating Centre for Cancer. Suspected cancer: recognition and referral. London: National Institute for Health and Care Excellence, 2015.

The negative predictive value of a negative repeat urinalysis in patients presenting with haematuria: A review of 1138 patients